Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Income Statement

Compare
166 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q3 2024), Inhibikase Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Inhibikase Therapeutics's net income was $-5.78M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 260.50K$ 123.44K$ 3.10M$ 698.47K
Gross Profit
$ 0.00$ -13.36M$ 116.72K$ -8.26M$ -195.33K
Operating Expenses
$ 28.59M$ 6.73M$ 18.13M$ 14.77M$ 2.82M
Depreciation and Amortization
$ 0.00$ 177.40K$ 6.72K$ 14.77M$ 2.82M
EBITDA
$ -28.59M$ -19.91M$ -18.12M$ -14.77M$ -2.82M
Operating Income
$ -28.59M$ -20.09M$ -18.13M$ -14.77M$ -2.82M
Other Income/Expenses
$ 1.07M$ 1.06M$ 74.45K$ -19.92K$ -29.40K
Pretax Income
$ -27.52M$ -19.03M$ -18.05M$ -14.79M$ -2.85M
Net Income
$ -27.52M$ -19.03M$ -17.91M$ -14.81M$ -2.88M
Per Share Metrics
Basic EPS
$ -1.16$ -3.57$ -4.26$ -4.88$ -1.72
Diluted EPS
$ -1.16$ -3.57$ -4.26$ -4.88$ -1.72
Weighted Average Shares Outstanding
23.71M 5.33M 4.20M 3.03M 1.68M
Weighted Average Shares Outstanding (Diluted)
23.71M 5.33M 4.20M 3.03M 1.68M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis